An Australian vote for pharma: biosimilars
This article was originally published in Scrip
Executive Summary
Somatropin is the only biosimilar product on the Australian market. (In Europe, by contrast, 17 biosimilars of five different molecules have been approved since 2006.) This synthetic growth hormone recorded sales of $45,000 in 2009, although the market is still very much dominated by the original branded product: Pfizer's Genotropin and Genotropin MiniQuick. Three years after the first biosimilar was launched, the biosimilar somatropin market accounted for 0.4% of total somatropin sales.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.